A review of synthesis, biological activity, & docking studies of anti-tubercular agents

The World Health Organization suggests treating tuberculosis with a 6-month course of isoniazid (INH), rifampicin (RMP), ethambutol, and pyrazinamide. The anti-TB activity of a number of novel styryl-1,2,4-oxadiazoles against the MTB H37Ra strain was assessed. These compounds were motivated by the molecular structure of cinnamic acid. There is a substantial correlation between the antibacterial activity and the location of the pyridine substituent on the thiosemicarbazide skeleton. A total of thirty-three ligands were docked against the two proteins AftaA and EmbA during the primary protein-ligand docking process, which was carried out using iGemDock. The following study included eight anti-tuberculosis medications as a control group: rifampicin, isoniazid, bed aquiline, delamanid, ethionamide, ethambutol, Gemifloxacin, and thioacetazone.